TrialNature communications2026

The multi-kinase inhibitor tinengotinib as monotherapy or combined with atezolizumab in advanced solid tumors: a phase Ib/II trial.

Panpan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.